Page 169 - 2021_04-Haematologica-web

KCyd in high-risk NDMM
Engl J Med. 2008;359(9):906-917.
13. San-Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with pre- viously untreated multiple myeloma. J Clin
Oncol. 2013;31(4):448-455.
14. Benboubker L, Dimopoulos MA,
Dispenzieri A, et al. Lenalidomide and dex- amethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371(10):906-917.
15. Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301- 310.
16. Chng W-J, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017;31(6):1368-1374.
17. Avet-Loiseau H, Fonseca R, Siegel D, et al. Carfilzomib significantly improves the pro- gression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128(9):1174- 1180.
18. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dex- amethasone in patients with newly diag- nosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.
19. Bringhen S, D’Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible
myeloma. Leukemia. 2018;32(4):979-985. 20.Bringhen S, Mina R, Petrucci MT, et al. Once-weekly versus twice-weekly carfil- zomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. Haematologica. 2019;
104(8):1640-1647.
21. Sonneveld P, Avet-Loiseau H, Lonial S, et al.
Treatment of multiple myeloma with high- risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.
22. Larocca A, Mina R, Offidani M, et al. First- line therapy with either bortezomib-mel- phalan-prednisone or lenalidomide-dexam- ethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two random- ized trials. Haematologica. 2020; 105(4):1074-1080.
23. Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonborte- zomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III ran- domized, controlled trials. J Clin Oncol. 2013;31(26):3279-3287.
24. Avet-Loiseau H, Bahlis NJ, Chng W-J, et al. Ixazomib significantly prolongs progression- free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017; 130(24):2610-2618.
25.Gay F, Cerrato C, Scalabrini DR, et al. Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide-
dexamethasone (KCd) induction-ASCT- KCd consolidation: analysis of the ran- domized FORTE trial in newly diagnosed multiple myeloma (NDMM). Blood. 2018;132(Suppl 1):Abstract #121 [ASH 2018 60th Meeting].
26. Gay F, Rota Scalabrini D, Belotti A, et al. Updated efficacy and MRD data according to risk status in newly diagnosed myeloma patients treated with carfilzomib plus lenalidomide or cyclophosphamide: results from the FORTE trial. HemaSphere. 2018;2(S1):6 [Abstract #S109, EHA 2018 23rd Congress].
27. Facon T, Kumar SK, Plesner T, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed mul- tiple myeloma (NDMM) ineligible for trans- plant (MAIA). Blood. 2018;132(Suppl 1):Abstract #LBA-2 [ASH 2018 60th Meeting].
28. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dex- amethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115.
29. Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melpha- lan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518-528.
30. Lakshman A, Painuly U, Rajkumar SV, et al. Impact of acquired del(17p) in multiple myeloma. Blood Adv. 2019;3(13):1930-1938.
31. Thakurta A, Ortiz M, Blecua P, et al. High subclonal fraction of 17p deletion is associat- ed with poor prognosis in multiple myelo- ma. Blood. 2019;133(11):1217-1221.
haematologica | 2021; 106(4)
1085